Life-Saving Choice: India Approves Emergency Price Hike for Critical Cancer Drugs Amid Acute Nationwide Shortage

NEW DELHI — In a rare and critical regulatory intervention, the Central government has granted in-principle approval to raise the prices of two cornerstone chemotherapy drugs, cisplatin and carboplatin, to combat an acute nationwide shortage that has severely disrupted cancer care across India. The emergency decision, greenlit under Para 19 of the Drug Prices Control Order (DPCO), allows the National Pharmaceutical Pricing Authority (NPPA) to bypass standard price ceilings for the public good, clearing the way for an anticipated 10% to 50% price increase in a bid to rescue a collapsing supply chain and restore manufacturing viability.

The Supply Crisis: Empty Shelves and Delayed Treatments

The nationwide shortage has escalated dramatically over the last few weeks, leaving patients and healthcare institutions in a precarious position. Across India, individuals arriving at oncology units for scheduled chemotherapy sessions have been turned away or forced to wait because vital medications are entirely out of stock.

According to Rajiv Singhal, general secretary of the All India Organisation of Chemists and Druggists (AIOCD), which represents 1.24 million members, the crisis has been brewing for months but recently reached a tipping point.

“There has been a supply crunch for two months, but it has become worse over the last two weeks with a severe shortage,” Singhal reported.

The NPPA is expected to finalize the precise adjusted tariff structures within the next 48 hours. The intervention specifically targets four critical medical formulations: the platinum-based chemotherapy agents cisplatin and carboplatin, along with two essential anti-tetanus injections.

Underlying Causes: The Soaring Cost of Precious Metals

The root cause of the current pharmaceutical deficit is a dramatic, unsustainable surge in global commodity pricing—specifically for platinum, which serves as the foundational Active Pharmaceutical Ingredient (API) base for both therapies.

Platinum Price Trajectory (Per Gram)
======================================
Sept 2025:  [████████]   ₹3,869
Feb 2026:   [█████████████████]  ₹8,000 (Peak)
April 2026: [████████████] ₹5,900 - ₹6,500 (Stabilized)
======================================

While market figures stabilized slightly by April 2026 to between ₹5,900 and ₹6,500 per gram, the sustained high costs rendered the government-mandated Maximum Retail Prices (MRPs) financially unviable for drug manufacturers.

“The shortage is primarily driven by a steep increase in platinum prices,” explained Mohan Jain, a company director of a prominent domestic oncology drug manufacturer. Jain noted that procurement costs for the raw metal escalated from roughly ₹2,000 to ₹5,500 per gram over the past year alone. Because the ceiling prices for these drugs were fixed under older regulatory cycles—some dating as far back as 2013—producers faced massive losses for every vial manufactured, leading to a widespread suspension of production lines.

Why These Regimens Are Indispensable

Both cisplatin and carboplatin are categorized under India’s National List of Essential Medicines (NLEM) and are heavily regulated to ensure public access. Introduced to clinical medicine decades ago, these platinum-based compounds are hailed as the “backbone of combination chemotherapy” due to their efficacy against a diverse spectrum of solid tumors.

First approved by the US Food and Drug Administration (FDA) in 1978, cisplatin revolutionized oncology, particularly for testicular cancer, turning it into a highly curable disease. Carboplatin, clinically introduced in 1981, offers a lower-toxicity profile, acting as an essential first-line alternative in combination with other therapeutics like paclitaxel.

Medical Experts and Policymakers Weigh In

The severe clinical reality of these shortages prompted high-level institutional warnings. The Tata Memorial Cancer Hospital, one of India’s premier oncology centers, formally raised an alarm regarding empty institutional inventories. In an official inter-ministerial communication, the NPPA highlighted that ensuring an uninterrupted supply of these first-line treatments is an absolute public health necessity.

For frontline oncologists, the shortage poses immediate, dangerous challenges to patient survival outcomes.

“When patients arrive for their scheduled chemotherapy and we don’t have cisplatin or carboplatin, we must either delay treatment or switch to less effective or more toxic alternatives,” says Dr. Ajit Kumar, an oncologist at a government hospital in New Delhi who was not involved in the regulatory proceedings. “This directly impacts survival outcomes, particularly for testicular and ovarian cancer patients where these specific drugs are the gold standard.”

The government has emphasized that this price correction is a highly localized measure, rather than a systemic policy shift. Pharma Secretary Manoj Joshi clarified that while the Ministry of Chemicals and Fertilizers is not contemplating a blanket price hike for all essential medicines, it will evaluate isolated, extreme cases where manufacturing has stalled due to volatile global input costs.

Public Health Implications for Patients

The immediate objective of the price hike is to give pharmaceutical companies the necessary cost leeway to resume production, stabilize supply chains, and get medications back onto hospital shelves. For patients, however, the policy shift presents a dual-edged sword:

• Treatment Continuity: The primary benefit is the rapid re-availability of dependable first-line therapies, preventing dangerous clinical delays in chemotherapy schedules.

• Increased Financial Burden: Though these generic drugs are fundamentally inexpensive—typically costing between ₹2,000 to ₹3,000 per month—a 10% to 50% price increase will inevitably translate to higher out-of-pocket healthcare expenses for vulnerable families.

Limitations and Counterarguments

While the emergency intervention has been widely welcomed as an essential stopgap measure, public health policy analysts note several critical vulnerabilities:

1. Supply Vulnerabilities and Import Reliance

The price adjustment fails to address India’s systemic reliance on imported platinum and key APIs. Geopolitical volatility in West Asia and shifting production dynamics in major mining nations like South Africa continue to threaten the stability of India’s pharmaceutical supply lines.

2. Socioeconomic Impact on Low-Income Patients

Even localized price increases can significantly affect impoverished patients who rely on free or subsidized care at government facilities, potentially straining state healthcare budgets.

3. Broad Shortage Scope Concerns

The emergency price waiver applies strictly to four specific formulations. Other essential platinum-based oncology therapeutics, such as oxaliplatin, remain bound to existing price caps and could experience similar production halts if global precious metal markets experience further shocks.

Looking Forward

Moving forward, the NPPA will utilize a legal framework designed for public emergencies to align the final retail prices with the real-world cost of raw materials. Per the directives of the government’s standing committee, the adjustments will stay strictly within the 10% to 50% corridor relative to previous pricing baselines.

While regulatory bodies finalize the technical pricing structures, thousands of cancer patients across India await a swift resumption of manufacturing—hoping that a modest increase in financial cost will finally secure their access to a lifetime of care.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• The Indian Express: Government clears price hike for key cancer drugs to tackle nationwide shortage, June 10, 2026. Source Link